
mAbxience will develop and manufacture the antibody for ONC001, a CD64-targeting ADC aimed at monocytic AML and chronic myelomonocytic leukemia.
Collect More Actionable Data and Optimize Yield with Real-Time Process Adjustments. Learn more how Viable Cell Density Monitoring works for your process in Hamilton’s eBook that features must-see examples of real applications using Hamilton viable cell density monitoring (Incyte) and total cell density monitoring (Dencytee).







